Paper Details

  1. Home
  2. Paper Details

Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.

Author: , AndrieuJean-Marie, ArakelyanNina, BerthouChristian, BrièreJosette, ColonnaPierre, DelwailVincent, DesablensBernard, JaisJean-Philippe, Moles-MoreauMarie-Pierre, SénécalDelphine

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study investigated the impact of a slightly reduced radiation dose on treatment outcomes for patients with early-stage Hodgkin lymphoma (HL). The study compared the effectiveness of a standard treatment regimen, including 3 cycles of ABVD chemotherapy and a tailored radiation schedule, to a regimen with a slightly reduced radiation dose.
Paper Details　
Original Abstract of the Article :
The combination of 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) and a tailored, extended irradiation schedule has been used to treat patients with early Hodgkin lymphoma (HL) in the authors' group since 1981. The randomized H97-E trial (1997-2004) was designed to assess th...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/cncr.25295

データ提供：米国国立医学図書館（NLM）

Hodgkin Lymphoma: Tailoring Radiation Therapy

Hodgkin lymphoma, a type of cancer affecting the lymph nodes, is like a desert oasis – it can be beautiful, but it can also be dangerous. This study investigated the impact of slightly reduced irradiation doses on the freedom from treatment failure (FFTF) rate in patients with early-stage Hodgkin lymphoma who had already received three cycles of ABVD chemotherapy. This is like carefully choosing the right amount of water to conserve in the desert, trying to find a balance between survival and avoiding dehydration.

Finding the Right Balance

The researchers wanted to know if slightly reducing the radiation dose would still be effective in fighting the cancer while potentially minimizing side effects. It's like finding the perfect spot in the oasis – not too close to the scorching sun, but not too far from the life-giving water. They found that while reducing the radiation dose didn't negatively impact the FFTF rate, it didn't significantly improve it either.

Precision Medicine in Action

This study highlights the importance of tailoring treatment plans based on the individual needs of each patient. It's like recognizing that different parts of the desert require different strategies for survival. Just as a traveler might choose to carry extra water in a harsh section of the desert, patients with early-stage Hodgkin lymphoma might need different radiation doses depending on their specific circumstances.

Dr.Camel's Conclusion

This randomized trial demonstrates the potential for tailoring radiation therapy in early-stage Hodgkin lymphoma, aiming for a balance between efficacy and minimizing side effects. It's like finding the sweet spot in the desert, where we can combat the disease without overwhelming our patients. This research shows the importance of individualized treatment approaches in cancer care.
Date :
  1. Date Completed 2010-10-12
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

20564152

DOI: Digital Object Identifier

10.1002/cncr.25295

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.